ATEA PHARMACEUTICALS
Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.
ATEA PHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.ateapharma.com
Total Employee:
51+
Status:
Active
Total Funding:
283.43 M USD
Technology used in webpage:
Person Schema Gravatar Profiles Akamai Hosted
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Fedora Pharmaceuticals
Fedora Pharmaceuticals engages in the discovery and development of antibiotics for life-threatening microbial drug resistance needs.
Idenix Pharmaceuticals
Idenix Pharmaceuticals is focused on the discovery and development of drugs for the treatment of human viral diseases.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series D - Atea Pharmaceuticals
Sectoral Asset Management
Sectoral Asset Management investment in Series D - Atea Pharmaceuticals
Ally Bridge Group
Ally Bridge Group investment in Series D - Atea Pharmaceuticals
Redmile Group
Redmile Group investment in Series D - Atea Pharmaceuticals
Morningside Venture Investments
Morningside Venture Investments investment in Series D - Atea Pharmaceuticals
Perceptive Advisors
Perceptive Advisors investment in Series D - Atea Pharmaceuticals
Rock Springs Capital
Rock Springs Capital investment in Series D - Atea Pharmaceuticals
T. Rowe Price
T. Rowe Price investment in Series D - Atea Pharmaceuticals
Cormorant Asset Management
Cormorant Asset Management investment in Series D - Atea Pharmaceuticals
Solasta Ventures
Solasta Ventures investment in Series D - Atea Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-10 | Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development |
Official Site Inspections
http://www.ateapharma.com Semrush global rank: 13.11 M Semrush visits lastest month: 78
- Host name: 104.26.10.50
- IP address: 104.26.10.50
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Atea Pharmaceuticals"
About Us - Atea Pharmaceuticals
Leveraging the power of our medicinal chemistry expertise and discovery capabilities, we are focused on discovering, optimizing, and rapidly advancing novel drug candidates that have the potential to meet unmet medical needs or โฆSee details»
Our management team. - Our Team - Atea Pharmaceuticals
Atea is led by a team of highly experienced antiviral drug discoverers, developers and company builders, each bringing a unique perspective.See details»
Atea Pharmaceuticals, Inc | LinkedIn
Ir.ateapharma.com 110 3 Comments Like Comment Share Atea Pharmaceuticals, Inc 2,892 followers 11mo Report this post We're #hiring a new Director, Regulatory CMC in Massachusetts. Apply today or ...See details»
Investor Relations | Atea Pharmaceuticals, Inc.
Jan 15, 2025 Investor Relations Discovering and rapidly advancing potentially transformative antiviral therapies. Atea is a clinical stage biopharmaceutical company focused on discovering, โฆSee details»
Atea Pharmaceuticals - Crunchbase Company Profile & Funding
Atea Pharmaceuticals, Inc. โ Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at โฆSee details»
Atea Pharmaceuticals CEO and Key Executive Team | Craft.co
Atea Pharmaceuticals's Founder, Chairman & CEO is Jean-Pierre Sommadossi. Other executives include Andrea Corcoran, CFO & EVP, Legal; Wayne Foster, CAO & EVP and 21 others. See โฆSee details»
News Releases - Atea Pharmaceuticals, Inc.
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and โฆSee details»
Atea Pharmaceuticals - Craft
Oct 29, 2024 Atea Pharmaceuticals has 5 employees across 2 locations and $351.37 m in annual revenue in FY 2021. See insights on Atea Pharmaceuticals including office locations, โฆSee details»
Atea Pharmaceuticals - Bain Capital Life Sciences
Ateapharma.com. THEME. Inflection Capital. STATUS. active . Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to โฆSee details»
Atea Pharmaceuticals Expands Senior Management Team with
Jan 19, 2021 Senior executives bring proven industry experience to leadership roles in regulatory affairs and communications. BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Atea โฆSee details»
Atea - 2025 Company Profile, Funding & Competitors - Tracxn
Apr 12, 2025 Atea is a public company based in Boston (United States), founded in 2014 by Jean Pierre Sommadossi. It operates as a Developer of therapeutics for viral diseases.Atea โฆSee details»
Atea Pharmaceuticals Issues Statement Regarding Director
BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and โฆSee details»
Atea Pharmaceuticals, Inc Company Overview, Contact Details ...
May 20, 2020 [email protected]: 19%. [email protected]: [email protected]: 9%. [email protected]: [email protected]: 5%. See โฆSee details»
Our Science - Atea Pharmaceuticals
Uniquely active against RNA viruses. Nucleic acids are composed of naturally occurring chemical compounds termed nucleosides and nucleotides and are the main information-carrying โฆSee details»
Atea Pharmaceuticals Strengthens Management Team with โฆ
Aug 24, 2020 Executive Vice President of Clinical Sciences and Vice President of Regulatory Bring Decades of Clinical and Regulatory Experience BOSTON, Mass., August 24, 2020 โ โฆSee details»
Atea Pharmaceuticals Inc. - Cruelty Free Investing
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral โฆSee details»
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation โฆ
Sep 26, 2022 The World Health Organization has called dengue the most important mosquito-borne viral disease in the world. The FDA, together with other governmental and non โฆSee details»
Atea Pharmaceuticals, Inc. (Atea Pharmaceuticals, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ โฆ
6 days ago ABSTRACT AT-752 is a novel guanosine nucleotide prodrug inhibitor of the dengue virus (DENV) polymerase with sub-micromolar, pan-serotype antiviral activity. This phase 1, โฆSee details»
Careers - Atea Pharmaceuticals
All official Atea emails sent to potential candidates will come from the domain @ateapharma.com. If you have been defrauded or suspect identity theft as a result of an employment scam, โฆSee details»
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results โฆ
5 hours ago BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in โฆSee details»